ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.9626
0.11%
Brent Oil
84.045
0.60%
Bitcoin
57,747.67
-0.84%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Atara Biotherapeutics Inc (ATRA)

  7. Atara Biotherapeutics Inc (ATRA) Noticias

ATRA Atara Biotherapeutics Inc

0.6845
0.00 (0.00%)
Pre Mercado
Última actualización: 04:10:40
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Atara Biotherapeutics Inc ATRA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 0.6845 04:10:40
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.6845
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
05/4/202415:01BWAtara Biotherapeutics, Inc. Reports Inducement Grant Under..
28/3/202407:30BWAtara Biotherapeutics Announces Fourth Quarter and Full Year..
06/3/202417:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202417:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202419:21EDGAR2Form 144 - Report of proposed sale of securities
04/3/202419:19EDGAR2Form 144 - Report of proposed sale of securities
04/3/202419:18EDGAR2Form 144 - Report of proposed sale of securities
04/3/202419:17EDGAR2Form 144 - Report of proposed sale of securities
29/2/202408:05BWAtara Biotherapeutics Receives FDA Clearance of IND..
28/2/202415:30BWAtara Biotherapeutics to Participate in Cell Therapy Panel..
23/2/202415:30EDGAR2Form 8-K - Current report
14/2/202408:00BWAtara Biotherapeutics Announces Submission of..
01/2/202401:25PRNUSAtara Biotherapeutics and Pierre Fabre Laboratories Announce..
31/1/202417:30BWAtara Biotherapeutics and Pierre Fabre Laboratories Announce..
09/1/202415:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/1/202415:01EDGAR2Form 8-K - Current report
08/1/202408:00BWAtara Biotherapeutics Announces $15 Million Registered..
08/1/202407:11EDGAR2Form 8-K - Current report
08/1/202407:00BWAtara Biotherapeutics to Present Recent Progress and Key..
04/1/202415:01BWAtara Biotherapeutics to Present at the 42nd Annual J.P...
03/1/202415:09EDGAR2Form S-8 - Securities to be offered to employees in employee..
20/12/202315:30EDGAR2Form 8-K - Current report
20/12/202315:01BWAtara Biotherapeutics Announces Closing of Expanded Global..
11/12/202311:00BWAtara Biotherapeutics Presents Positive Preclinical Data on..
01/12/202315:01BWAtara Biotherapeutics, Inc. Reports Inducement Grants Under..
29/11/202317:05BWAtara Biotherapeutics To Present Positive New Tab-cel®..
22/11/202315:01BWAtara Biotherapeutics to Participate at the 6th Annual..
20/11/202316:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202316:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202316:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202316:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202316:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/11/202316:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202315:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
10/11/202315:01BWAtara Biotherapeutics To Participate at the Stifel..
08/11/202316:35BWAtara Biotherapeutics Announces Primary Analysis Data from..
01/11/202316:25EDGAR2Form S-3 - Registration statement under Securities Act of..
01/11/202315:05EDGAR2Form 8-K - Current report
01/11/202307:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202307:35EDGAR2Form 8-K - Current report
01/11/202307:30BWAtara Biotherapeutics Announces Expanded Global Tab-cel®..
06/10/202315:01BWAtara Biotherapeutics, Inc. Reports Inducement Grants Under..
19/9/202315:50DJNAtara Biotherapeutics to Submit New FDA Biologics License..
19/9/202315:01BWAtara Biotherapeutics Announces Plans to Submit Tab-cel® BLA..

Su Consulta Reciente

NASDAQ
ATRA
Atara Biotherapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados